GlassScriptPhysician profile
Tracy D Arnold
NPI 1952660300
$2,416.90
in general payments reported to CMS, 2019-2025
31 companies · $98.02 in 2025
The $98.02 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $303 · 2022: $954 · 2023: $989 · 2024: $73.62 · 2025: $98.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $551.05 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $420.28 | 2022-2023 | |
| Sk Life Science, INC. | $161.44 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $138.45 | 2022-2023 | Ongentys, Ingrezza |
| Sumitomo Pharma America, INC. | $123.13 | 2023 | Aptiom |
| Eisai INC. | $122.69 | 2021-2022 | |
| Amgen INC. | $90.00 | 2021-2023 | Otezla |
| Sunovion Pharmaceuticals INC. | $83.40 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $76.38 | 2022 | |
| Supernus Pharmaceuticals, INC. | $56.89 | 2021-2022 | |
| Pfizer INC. | $55.76 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $51.11 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $50.94 | 2023 | Keveyis |
| Novo Nordisk INC | $47.74 | 2021-2022 | |
| Lilly USA, LLC | $46.42 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $37.18 | 2022 | |
| Grifols USA, LLC | $35.65 | 2023 | Gamunex-C |
| Kowa Pharmaceuticals America, INC. | $31.78 | 2022 | |
| Csl Behring | $30.39 | 2023 | Hizentra |
| Axsome Therapeutics, INC. | $23.50 | 2023 | Sunosi |
| Ucb, INC. | $21.88 | 2024 | Nayzilam |
| Arbor Pharmaceuticals, INC. | $20.80 | 2021 | |
| Lundbeck LLC | $18.71 | 2023 | Rexulti |
| Avanir Pharmaceuticals, INC. | $18.25 | 2022 | |
| Amneal Pharmaceuticals LLC | $17.67 | 2023 | Rytary |
| Acorda Therapeutics, INC | $16.67 | 2023 | Inbrija |
| Argenx US, INC. | $16.10 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.58 | 2021 | |
| Agile Therapeutics, INC. | $13.06 | 2021 | |
| Alexion Pharmaceuticals, INC. | $12.90 | 2023 | Ultomiris |
| Neurelis, INC. | $12.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.